Abstract: The invention relates to a cell line expressing the gamma chain of the Fc?RI receptor and human CD303 antigen, characterized in that said cell line is transfected in a stable manner by an expression vector comprising a nucleic acid molecule coding for human CD303 antigen and having strong expression of human CD303 on the surface thereof, e.g. at least 10000 molecules of human CD303 per cell, as well as a vector or vector kit that can be used to co-express the gamma chain of the Fc?RI receptor and human CD303 antigen, and different uses of the cell line of the invention.
Type:
Grant
Filed:
March 31, 2016
Date of Patent:
March 26, 2019
Assignee:
LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
Inventors:
Nathalie Fournier, Christophe De Romeuf
Abstract: In one aspect, the disclosure relates to highly galactosylated anti-TNF-alpha antibodies and compositions thereof. In one aspect, the disclosure relates to populations of anti-TNF-alpha antibodies with a high level of galactosylation, and compositions thereof. In one aspect, the disclosure relates to methods of production and use of highly galactosylated anti-TNF-alpha antibodies and populations of anti-TNF-alpha antibodies with a high level of galactosylation. In some embodiments, the anti-TNF-alpha antibody is adalimumab.
Type:
Grant
Filed:
February 13, 2014
Date of Patent:
January 8, 2019
Assignee:
Laboratoire Français du Fractionnement et des Biotechnologies
Abstract: The present invention relates to a device for processing a biological fluid comprising cells suspended in a liquid, the processing device being intended for use in a centrifugation step to separate the cells from the liquid, the processing device comprising: a pouch suitable for receiving the biological fluid, the pouch having top and bottom edges that are distanced from one another along a longitudinal axis, the pouch being composed of two flexible layers that are placed one atop the other and integrally interconnected along an interconnection area, the interconnection area being provided so as to form, between the two layers, an inner space for receiving the biological fluid and at least one opening suitable for placing the inner space in communication with an outer environment, at least one sealing member placed in the opening, for selectively opening and closing the opening, the processing device being characterized in that the inner space has: a top portion formed near the top edge and intended for re
Type:
Application
Filed:
December 16, 2016
Publication date:
December 20, 2018
Applicant:
Laboratoire Francais du Fractionnement et des Biotechnologies
Abstract: The present invention relates to the use of antibody Fc fragments in the treatment of autoimmune and/or inflammatory diseases, said Fc fragments being isolated recombinant Fc fragments having a modified affinity for at least one of the Fc receptors (FcR), particularly an increased affinity to FcRn.
Type:
Application
Filed:
July 6, 2016
Publication date:
December 13, 2018
Applicant:
Laboratoire Français du Fractionnement et des Biotechnologies
Inventors:
Philippe Mondon, Céline Monnet-Mars, Alexandre Fontayne, Christophe De Romeuf, Abdessatar Chtourou
Abstract: The present invention relates to a chimeric protein comprising at least one human amyloid P component and at least one fragment of an Fc region of a human antibody, the human amyloid P component and the fragment of an Fc region with which it is associated being bound to each other by means of a hinge region.
Type:
Application
Filed:
May 11, 2018
Publication date:
October 18, 2018
Applicant:
Laboratoire Francais du Fractionnement et des Biotechnologies
Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunization in Rh negative persons, in particular for hemolytic disease in a new-born baby of for uses such as idiopathic thrombocytopenic pupura 9ITP).
Type:
Grant
Filed:
June 7, 2017
Date of Patent:
September 25, 2018
Assignee:
LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
Inventors:
Roland Beliard, Dominique Bourel, Arnaud Glacet, Christophe de Romeuf, Nicolas Bihoreau, Emmanuel Nony
Abstract: The present invention relates to a class-G immunoglobulin against the anthrax toxin protective antigen (PA), or one of the fragments of same, comprising at least: a variable heavy-chain region comprising an amino acid sequence represented by the sequence SEQ ID NO: 1, or comprising an amino acid sequence having at least 90% identity with the sequence SEQ ID NO: 1, and comprising the amino acids Leucine in position 51 and Glycine in position 67, and a variable light-chain region comprising an amino acid sequence represented by the sequence SEQ ID NO: 2, or comprising an amino acid sequence having at least 90% identity with the sequence SEQ ID NO: 2, and comprising a Leucine amino acid in position 55. The invention also relates to the uses of such an immunoglobulin.
Type:
Grant
Filed:
January 16, 2015
Date of Patent:
August 28, 2018
Assignees:
LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES, ETAT FRANCAIS REPRESENTE PAR LE DIRECTEUR CENTRAL DU SERVICE DE SANTE DES ARMEES
Inventors:
Christian Behrens, Philippe Klein, Denis Hoguet
Abstract: In one aspect, the disclosure provides proteins with modified glycosylation and methods of their production. In aspect, the disclosure provides transgenic animals and cells for the production of proteins with modified glycosylation. In some embodiment, the modified glycosylation is increased sialylation.
Type:
Grant
Filed:
February 13, 2014
Date of Patent:
July 31, 2018
Assignee:
Laboratoire Français du Fractionnement et des Biotechnologies
Abstract: The present invention concerns an injectable composition comprising FVII and a filler, and its use for preventing or treating body and skin defects, especially folds, wrinkles, skin depressions and scars, while diminishing, decreasing or avoiding skin reactions due to injection, specially redness, ecchymosis, bruising, bleeding, erythema, oedema, necrosis, ulceration, swelling and/or inflammation.
Type:
Application
Filed:
June 10, 2016
Publication date:
June 21, 2018
Applicant:
Laboratoire Français du Fractionnement et des Biotechnologies
Inventors:
Abdessatar Chtourou, Jean-Luc Plantier, Philippe Mondon
Abstract: An anti-Factor VII affinity ligand that is particularly useful for purifying recombinant human activated Factor VII from transgenic sources. The affinity ligand combined with other orthogonal chromatographic steps allows the preparation of a highly purified FVII solution fully activated free of aggregates with a low percentage of degraded or oxidized FVII forms.
Type:
Grant
Filed:
July 18, 2013
Date of Patent:
May 29, 2018
Assignee:
LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
Inventors:
Damien Bataille, Michel Nogre, Abdessatar Sami Chtourou
Abstract: The invention relates to a composition strongly enriched with anti-A and/or anti-B polyclonal immunoglobulins, comprising polyclonal human immunoglobulins, characterised in that at least 80 wt.-% of the polyclonal human immunoglobulins present in the composition are anti-A or anti-B polyclonal human immunoglobulins, for use as a drug, particularly in the treatment of polycythemia and/or autoimmune diseases, and in particular peripheral autoimmune thrombocytopenia.
Type:
Application
Filed:
May 6, 2016
Publication date:
May 24, 2018
Applicant:
Laboratoire Francais du Fractionnement et des Biotechnologies
Abstract: In one aspect, the disclosure provides methods, cells and transgenic non-human mammals for the production of fusion proteins comprising one or more polypeptide fused to an Fc domain, as well as the fusion proteins comprising one or more polypeptide fused to an Fc domain obtained from these methods, cells and transgenic non-human mammals.
Type:
Application
Filed:
May 4, 2016
Publication date:
May 24, 2018
Applicants:
Laboratoire Français du Fractionnement et des, Biotechnologies, GIGA Entreprises
Abstract: A stable pharmaceutical composition in liquid form or in solid form, containing factor VII. The composition is free of mannitol, sucrose, and any antioxidant.
Type:
Grant
Filed:
May 26, 2016
Date of Patent:
May 15, 2018
Assignee:
Laboratoire Francais du Fractionnement et des Biotechnologies
Abstract: A pharmaceutical composition of recombinant human fibrinogen having a half-life of less than 12 hours and a pharmaceutically acceptable carrier or diluent. The pharmaceutical composition may also contain factor VIIa, factor VIII, von Willebrand's factor, or Desmopressin. The pharmaceutical composition may also contain divalent metal cations. The recombinant human fibrinogen may contain sialic acid.
Type:
Grant
Filed:
November 5, 2015
Date of Patent:
May 8, 2018
Assignee:
LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
Inventors:
Frank Pieper, Anurag Relan, Erik Jordahl Forsberg
Abstract: The present invention relates to a composition highly enriched in anti-A and/or anti-B polyclonal immunoglobulins, comprising human polyclonal immunoglobulins, characterized in that at least 80% by weight of the human polyclonal immunoglobulins present in the composition are human anti-A and/or anti-B polyclonal immunoglobulins. The invention also relates to a method for preparing such a composition, and to the use of the composition for preparing a positive control that can be used in a method for assaying anti-A and/or anti-B activity of human normal immunoglobulins, and to use of the composition for determining an individual's blood type.
Type:
Application
Filed:
May 6, 2016
Publication date:
April 12, 2018
Applicant:
Laboratoire Francais du Fractionnement et des Biotechnologies
Inventors:
Philippe PAOLANTONACCI, Catherine DE COUPADE, Stephane BOYER
Abstract: The invention relates to chimeric or humanised anti-CD303 antibodies to nucleic acids coding for the heavy and light chains of these antibodies, expression vectors, host cells, transgenic non-human animals or transgenic plants expressing said antibodies, as well as to the uses thereof in the treatment or prevention of blastic plasmacytoid dendritic cell neoplasms (BPDCN) or inflammatory diseases, in particular autoimmune diseases, involving plasmacytoid dendritic cells.
Type:
Application
Filed:
March 31, 2016
Publication date:
March 29, 2018
Applicant:
Laboratoire Francais du Fractionnement et des Biotechnologies
Inventors:
Nathalie FOURNIER, Alexandre FONTAYNE, Christophe de ROMEUF
Abstract: The invention relates to a method for the purification of a therapeutic protein from transgenic milk, comprising a clarification step using a salt of poly(diallyldimethylammonium).
Type:
Application
Filed:
April 1, 2016
Publication date:
March 22, 2018
Applicant:
Laboratoire Francais du Fractionnement et des Biotechnologies
Abstract: The invention relates to a cell line expressing the gamma chain of the Fc?RI receptor and human CD303 antigen, characterised in that said cell line is transfected in a stable manner by an expression vector comprising a nucleic acid molecule coding for human CD303 antigen and having strong expression of human CD303 on the surface thereof, e.g. at least 10000 molecules of human CD303 per cell, as well as a vector or vector kit that can be used to co-express the gamma chain of the Fc?RI receptor and human CD303 antigen, and different uses of the cell line of the invention.
Type:
Application
Filed:
March 31, 2016
Publication date:
March 8, 2018
Applicant:
Laboratoire Francais du Fractionnement et des Biotechnologies
Inventors:
Nathalie FOURNIER, Christophe DE ROMEUF
Abstract: A kit for the determination of the thrombogenic power of human immunoglobulins contained in a biologically acceptable product. Also a process making it possible to determine the thrombogenic power linked to the presence of activated Factor XI and/or activated Factor IX and/or activated Factor XII, and/or activated Factor VII and/or activated Factor X in a sample capable of being administered to humans.
Type:
Grant
Filed:
November 18, 2011
Date of Patent:
February 13, 2018
Assignee:
LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
Abstract: The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.
Type:
Grant
Filed:
May 1, 2015
Date of Patent:
January 30, 2018
Assignee:
LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
Inventors:
Dominique Bourel, Sylvie Jorieux, Christophe de Romeuf, Philippe Klein, Christine Gaucher, Nicolas Bihoreau, Emmanuel Nony